Retatrutide reaches 30.3% weight loss in Phase 3
The triple agonist clears its pivotal obesity programme. Filing is planned for Q1 2027, which puts a prescription eighteen to twenty-four months away.
The triple agonist clears its pivotal obesity programme. Filing is planned for Q1 2027, which puts a prescription eighteen to twenty-four months away.
All-in monthly cost at 10 mg
TRIUMPH-1, the 80-week Phase 3 weight-management trial, produced mean weight reduction up to 30.3%, with TRIUMPH-2 and TRIUMPH-3 topline following in July 2026.
For context, a review of 26 randomised trials across 15,491 adults placed retatrutide at 24.2% against tirzepatide's 17.8% and subcutaneous semaglutide's 13.9% at maximum evaluated doses.
It is not available and will not be compounded. Anything sold today as compounded or research-grade retatrutide is an unapproved substance outside clinical oversight.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement, the pharmacy licensing framework or the clinical review behind a prescription.
The cheapest verified compounded route we track currently sits at $215 a month all-in at a 10 mg maintenance dose, about $2,580 for a first year. Where a development moves that figure, our tables move with it on the next build.
How to verify this yourself
Regulatory claims should be checked against the agency rather than against coverage of the agency. FDA publishes warning letters searchable by company name, a shortage database, and its compounding pages. Trial claims should be checked against the registry entry rather than a press release.
Every source behind this item is linked below, and where a story is still moving we say so rather than implying it is settled.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.